Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. - Wikidata - awgldk - TriplyDB

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

http://www.wikidata.org/entity/Q37993908

about

Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenografts Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients.Single compartment drug delivery.Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment Nanocrystals for the parenteral delivery of poorly water-soluble drugs Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: review of animal models.Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis.Multifunctional platinum-based nanoparticles for biomedical applications.A model based analysis of IPEC dosing of paclitaxel in rats.Uptake of Eudragit Retard L (Eudragit® RL) Nanoparticles by Human THP-1 Cell Line and Its Effects on Hematology and Erythrocyte Damage in Rats.Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals.Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model.Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer.High-Pressure Nebulization as Application Route for the Peritoneal Administration of siRNA Complexes.Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers.Studies on assessment methods of malignant ascites residue and changes of verapamil concentration in intraperitoneal perfusion chemotherapy.

P2860

Q30421398-D885DCBA-B769-4681-BBDE-C1752F58A2DB Q33829621-C691C9B0-2619-4778-844C-C7ECC3442C6B Q34263907-4947782F-939A-4E6B-992C-02C5BF8F9141 Q35032664-A0869C09-A1EC-473E-B7C9-C35CD264CB39 Q35777174-AB84CD89-1C83-45BD-BCC7-BED80CEB8E99 Q35868066-1B861757-D425-413C-B5CB-15490C042CA0 Q37309461-BBA09B9A-D887-4108-996C-744168C5B06D Q38104343-DBA2EDB3-394C-4FA7-885E-FC43EA7099E7 Q38152303-EF7D5A57-2955-4105-B4F6-5A4E04B9FD7E Q38199370-49E4A44B-CFAC-4DF4-9BE3-247432E1EE2B Q38812240-6FF7E038-463E-4539-A35F-1D3E016CD7CB Q38993050-1FDD4FC6-33EF-40AB-8E7F-58B712767BD2 Q39020781-056699DE-0D14-4413-94FF-A2080E671D75 Q40379327-D8F8DA86-F11E-425B-A59B-1DA029EC2BB9 Q42321339-E725AFF4-F20E-4071-A45B-9AFFFA9B5F21 Q47619786-1CD37423-F1F1-48B1-9B0D-00980F4F0EA2 Q47643972-6DB3C7C7-F785-4C69-A78F-53EABD764B38 Q48762735-32DA6C48-7D0C-4009-8D26-639F989D4D4C Q50245206-BD3D107A-8D9F-4906-BB6B-7E0CDD1896E2 Q53501359-2C4CF3BA-A496-4C71-A10B-CB11444C0C99

P2860

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

http://www.wikidata.org/entity/Q37993908

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

@en

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

@nl

type

label

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

@en

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

@nl

prefLabel

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

@en

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

@nl

P1433

Q37993908-8C4E4CB0-3A08-44A4-813A-EA6AEF620AE2

P1476

Q37993908-3F9899F7-9431-46B5-AD32-83D24337C119

P2093

Q37993908-490517CF-65CB-467D-82B5-5E8276AA2752

Q37993908-91B63D21-F2DE-4392-8E14-C5F883A5D35D

P2860

Q37993908-023778D9-5F32-4AD6-A9A4-481DF318150F

Q37993908-034D31D4-E3AE-44F4-B2B9-D8B6CE9A51DE

Q37993908-083B3985-36E6-4B9C-9914-6F31CBEE57F2

Q37993908-099F97E5-F408-48A8-8F38-7DCBE6ACDE95

Q37993908-0C913BAA-885E-41BE-BFBF-879755B9A697

Q37993908-0D077930-EC89-44DE-AFE6-5B0294AAD83A

Q37993908-0D592E93-A6D7-43CB-B2EB-909A8CD11894

Q37993908-107B852A-2580-4910-B4F1-E96CF3748E8A

Q37993908-11960E02-2C91-4E90-8C55-B8AC33E57C2A

Q37993908-142694DD-23BF-43BF-AB86-A68C8DBA3D13

P2888

Q37993908-908BCB66-BD87-48CC-8C44-E923A1A424FE

P304

Q37993908-ACEC6B01-7885-42FB-B881-48F2A5693AB2

P31

Q37993908-FAFFBF92-CB97-4D7F-AB88-6DE219F515F5

P356

Q37993908-6DA5B9F6-E00E-4D64-9B00-D0F663717966

P433

Q37993908-F6BC0839-2DC4-4BB8-B178-4C3DAD204B73

P478

Q37993908-7A92BBB7-557F-4487-97A9-3204EDA3A602

P577

Q37993908-B0D6A829-9FC4-4F6C-92B7-E8991795102C

P6179

Q37993908-E2ED85C7-BA7C-45F5-AC9B-25BBB57644EB

P698

Q37993908-2F548D97-41AA-4A2D-AC73-AE2022164277

P921

Q37993908-4FFE20FF-D294-4611-B182-AA5281FEB39E

P356

11598890-000000000-00000

P1433

Clinical Pharmacokinetics

P1476

Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

@en

P2093

Csilla Hasovits

http://www.w3.org/2001/XMLSchema#string

Stephen Clarke

http://www.w3.org/2001/XMLSchema#string

P2860

Catumaxomab: clinical development and future directions

A phase I and pharmacokinetic study of intraperitoneal topotecan

Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.

Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.

A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.

Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.

Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.

Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei.

P2888

11598890-000000000-00000

P304

203-224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11598890-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043958925

http://www.w3.org/2001/XMLSchema#string

P698

22420577

http://www.w3.org/2001/XMLSchema#string

P921